20210916. Evopoint, SinoMab and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
Evopoint and SinoMab will receive USD $12 million in initial upfront payments and up to $549 million as future development, regulatory, and commerci...
More